talimogene laherparepvec诱发大疱性类天疱疮。 - Suppr

Suppr

超能文献

Talimogene laherparepvec induced bullous pemphigoid.

作者信息

Davoudi Sahar, Mahmoud Fade, Abbott Jordan

机构信息

University of Arizona College of Medicine, Tucson, Arizona.

Division of Hematology and Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona.

出版信息

JAAD Case Rep. 2025 Apr 2;60:115-117. doi: 10.1016/j.jdcr.2025.03.016. eCollection 2025 Jun.

DOI:10.1016/j.jdcr.2025.03.016

PMID:40417130

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12098019/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/628a/12098019/3f38b2c449a3/gr1.jpg

相似文献

Talimogene laherparepvec induced bullous pemphigoid.

JAAD Case Rep. 2025 Apr 2;60:115-117. doi: 10.1016/j.jdcr.2025.03.016. eCollection 2025 Jun.

Local intralesional talimogene laherparepvec therapy with complete local response in oral palatine mucosal melanoma: a case report.

J Med Case Rep. 2024 May 23;18(1):257. doi: 10.1186/s13256-024-04554-8.

Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.

BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y.

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.

Adv Ther. 2019 Jan;36(1):101-117. doi: 10.1007/s12325-018-0850-6. Epub 2018 Dec 7.

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.

Cancer Immunol Immunother. 2017 Jun;66(6):683-695. doi: 10.1007/s00262-017-1967-1. Epub 2017 Feb 25.

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.

Head Neck. 2016 Dec;38(12):1752-1758. doi: 10.1002/hed.24522. Epub 2016 Jul 13.

The safety of talimogene laherparepvec for the treatment of advanced melanoma.

Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.

Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.

Melanoma Res. 2018 Jun;28(3):250-255. doi: 10.1097/CMR.0000000000000444.

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.

Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma.

Adv Ther. 2016 Apr;33(4):643-57. doi: 10.1007/s12325-016-0313-x. Epub 2016 Mar 15.

本文引用的文献

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.

J Am Acad Dermatol. 2023 Jun;88(6):1265-1270. doi: 10.1016/j.jaad.2023.02.017. Epub 2023 Mar 21.

Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.

Br J Dermatol. 2022 Dec;187(6):981-987. doi: 10.1111/bjd.21836. Epub 2022 Sep 6.

A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes.

J Am Acad Dermatol. 2022 Dec;87(6):1394-1395. doi: 10.1016/j.jaad.2022.08.001. Epub 2022 Aug 5.

Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.

Front Immunol. 2022 Jul 22;13:953546. doi: 10.3389/fimmu.2022.953546. eCollection 2022.

Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.

JAMA Dermatol. 2022 Aug 1;158(8):933-941. doi: 10.1001/jamadermatol.2022.1624.

Immune checkpoint inhibitor-related dermatologic adverse events.

J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132. Epub 2020 May 23.

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

Lancet Oncol. 2018 Nov;19(11):1480-1492. doi: 10.1016/S1470-2045(18)30700-9. Epub 2018 Oct 22.

Three case reports of post immunization and post viral Bullous Pemphigoid: looking for the right trigger.

BMC Pediatr. 2017 Feb 23;17(1):60. doi: 10.1186/s12887-017-0813-0.

The safety of talimogene laherparepvec for the treatment of advanced melanoma.

Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验